预测氯氮平血药浓度低于350 ng/mL的临床风险评分列线图:开发与验证
该回顾性队列研究基于单因素和多因素logistic回归识别氯氮平血药浓度低于350 ng/mL的独立危险因素,并构建列线图预测模型。多因素分析显示日剂量(OR=0.987)和性别(OR=3.863)为独立影响因素,模型AUC为0.760,校准曲线一致性指数为0.764,决策曲线显示净获益范围为10%至62%。
要点
- 日剂量和性别是氯氮平血药浓度低于350 ng/mL的独立影响因素。
- 列线图模型具有良好区分度(AUC=0.760)和校准度(C指数=0.764)。
- 男性达350-600 ng/mL所需日剂量228.8-392.2 mg,女性154.2-264.3 mg。
核心结论
- 构建的列线图能有效预测氯氮平血药浓度低于治疗阈值的风险水平。
研究设计与样本
- 回顾性队列研究,经西安精神卫生中心伦理委员会批准(XAJWKY-2024034),采用单因素和多因素logistic回归分析识别独立危险因素并构建列线图预测模型。
主要发现
- 多因素logistic回归显示日剂量(OR=0.987,95%CI:0.984-0.990,P<0.001)和性别(OR=3.863,95%CI:2.597-5.746,P<0.001)是亚治疗浓度氯氮平的独立影响因素。
- 列线图模型曲线下面积为0.760,校准曲线一致性指数为0.764。
- 决策曲线分析显示列线图预测亚治疗浓度风险的净获益范围为10%至62%。
- 男性患者达到350-600 ng/mL血药浓度所需的氯氮平日剂量范围为228.8至392.2 mg,女性为154.2至264.3 mg。
关键数值与推荐
- 预测模型纳入日剂量和性别两个预测因子,AUC为0.760,一致性指数为0.764,净获益范围10%至62%。
- 男性达350-600 ng/mL所需日剂量228.8-392.2 mg,女性为154.2-264.3 mg。
临床怎么用
- 可基于日剂量和性别使用列线图快速评估患者氯氮平血药浓度低于350 ng/mL的风险。
- 对高风险患者可考虑结合治疗药物监测调整剂量,男性可能需要更高日剂量以达到目标浓度。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
AIMS: A plasma clozapine concentration below 350 ng/mL may result in treatment failure; however, a rapid method for predicting whether a patient's plasma concentration meets this threshold is lacking. This study aimed to develop a nomogram to predict the risk of subtherapeutic clozapine concentrations in treated patients. METHODS: Univariate and multivariate logistic regression analyses were performed to identify independent risk factors associated with subtherapeutic clozapine concentrations. A predictive nomogram prediction model was then constructed based on these factors. The ethics committee of the Xi'an Mental Health Center approved the study (XAJWKY-2024034). RESULTS: Multivariate logistic regression analysis identified daily dose (OR = 0.987, 95% CI: 0.984-0.990, P < 0.001) and sex (OR = 3.863, 95% CI: 2.597-5.746, P < 0.001) as independent factors influencing the subtherapeutic concentrations of clozapine. A predictive nomogram was constructed based on a multivariable prediction model, which demonstrated good accuracy and discriminative ability, with an area under the curve of 0.760. Validation of the model's calibration curve resulted in a concordance index of 0.764. A decision curve analysis revealed that the nomogram predicting the risk of subtherapeutic plasma clozapine concentrations exhibited a greater net benefit value, ranging from 10% to 62%. Additionally, our research indicated that the daily dosage of clozapine required for male patients to achieve a plasma concentration of 350-600 ng/mL ranges from 228.8 to 392.2 mg, whereas it ranges from 154.2 to 264.3 mg for female patients. CONCLUSIONS: The constructed nomogram was effective at predicting the risk level associated with subtherapeutic clozapine plasma concentrations.
引用
- Ding J, Liu J, Zhai Y, et al. Development and validation of a clinical risk score nomogram for predicting clozapine plasma concentrations below 350 ng/mL: A retrospective cohort study. Br J Clin Pharmacol. 2025. PMID: 41423351. doi:10.1002/bcp.70411
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。